“Aldevron continuously seeks opportunities to better serve our clients and the field of advanced therapies through our high-quality products and services, enabling breakthrough science to become transformational medicines,” said Michelle Berg, President, GMP Nucleic Acids with Aldevron. “We are excited to offer pALD-HELP, given its extensive track record in clinical research. Providing this in a readily available option allows for more streamlined access at a variety of quality levels and without royalty fees through commercial production. Aldevron’s broadening portfolio of standardized products provides a clearer path to better facilitate these potential therapies to reach patients sooner.”
Aldevron has more than 23 years of experience manufacturing high-quality custom products that are used by companies around the world, along with a catalog of products that provide a consistent, reliable option to help clients meet deadlines. In addition to the AAV construct suite, Aldevron’s inventory product lines also include lentivirus plasmids, IVT enzymes, and a variety of CRISPR nucleases.